Crossmark

Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Crossref DOI link: https://doi.org/10.1186/s12967-021-03111-x

Published Online: 2021-10-16

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xiaojuan

Qi, Shaoyan

Duan, Xiaoguang

Han, Bing

Zhang, Shuguang

Liu, Shaohua

Wang, Haixu

Zhang, Haibo

Sun, Tongwen http://orcid.org/0000-0001-6536-3222
Funding

Funding for this research was provided by:

United Fund of National Natural Science Foundation of China (U2004110)

Leading Talents Fund in Science and Technology Innovation in Henan Province (194200510017)

Science and Technology people-benefit project of Zhengzhou (2019KJHM0001)

The special fund for young and middle-aged medical research of China International Medical Exchange Foundation (Z-2018-35)

The integrated thinking research foundation of the China foundation for International Medical Exchange (Z-2016-23-2001)

Overseas Training Program of Health Science and Technology Talents in Henan Province (HWYX2019008)
License Information

Text and Data Mining valid from 2021-10-16

Version of Record valid from 2021-10-16
More Information

Article History

Received: 14 March 2021

Accepted: 7 October 2021

First Online: 16 October 2021

Declarations

:

: The study was approved by the institutional research ethics committee of The First Affiliated Hospital of Zhengzhou University, and waived informed consent based on the real-world design and anonymization of patient identifiers before analysis.

: Not applicable.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below